271 related articles for article (PubMed ID: 17318789)
1. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Kassab S; Garadah T; Abu-Hijleh M; Golbahar J; Senok S; Wazir J; Gumaa K
J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):206-11. PubMed ID: 17318789
[TBL] [Abstract][Full Text] [Related]
2. [Effects of RNA interference targeting angiotensin 1a receptor on the blood pressure and cardiac hypertrophy of rats with 2K1C hypertension].
Zhang JQ; Sun HL; Ma YX; Wang DW
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(16):1138-43. PubMed ID: 16796846
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Ke YS; Cao H; Yang T
Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
[TBL] [Abstract][Full Text] [Related]
4. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
5. Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
Xiang Y; Huang J
Acta Pharmacol Sin; 2000 Sep; 21(9):850-4. PubMed ID: 11501170
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
[TBL] [Abstract][Full Text] [Related]
7. Ameliorative role of rosiglitazone in hyperhomocysteinemia-induced experimental cardiac hypertrophy.
Pal Singh A; Kaur T; SinghDahiya R; Singh N; Singh Bedi PM
J Cardiovasc Pharmacol; 2010 Jul; 56(1):53-9. PubMed ID: 20351560
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat.
Whaley-Connell A; Govindarajan G; Habibi J; Hayden MR; Cooper SA; Wei Y; Ma L; Qazi M; Link D; Karuparthi PR; Stump C; Ferrario C; Sowers JR
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E355-63. PubMed ID: 17440033
[TBL] [Abstract][Full Text] [Related]
9. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats.
Singh AP; Singh M; Balakumar P
J Cardiovasc Pharmacol; 2008 Jun; 51(6):596-604. PubMed ID: 18520950
[TBL] [Abstract][Full Text] [Related]
10. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats.
Wang T; Yin KS; Liu KY; Lu GJ; Li YH; Chen JD
Chin Med J (Engl); 2008 Nov; 121(22):2312-9. PubMed ID: 19080339
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
Tachikawa H; Kodama M; Hui L; Yoshida T; Hayashi M; Abe S; Kashimura T; Kato K; Hanawa H; Watanabe K; Nakazawa M; Aizawa Y
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S105-10. PubMed ID: 12688405
[TBL] [Abstract][Full Text] [Related]
14. [Signal transductional mechanism of calpain involved in the regulation of rat hypertrophy myocardium mediated by overloaded pressure].
Yang YJ; Liu HM; Zhang X; Zhang JH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):599-602, 648. PubMed ID: 17718420
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Biala A; Finckenberg P; Korpi A; Loytainen M; Martonen E; Levijoki J; Mervaala E
J Physiol Pharmacol; 2011 Jun; 62(3):275-85. PubMed ID: 21893687
[TBL] [Abstract][Full Text] [Related]
16. Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond.
Dahlöf B
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S14-6. PubMed ID: 17199213
[TBL] [Abstract][Full Text] [Related]
17. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats.
Baba HA; Iwai T; Bauer M; Irlbeck M; Schmid KW; Zimmer HG
J Mol Cell Cardiol; 1999 Feb; 31(2):445-55. PubMed ID: 10093056
[TBL] [Abstract][Full Text] [Related]
19. [Activation of the renin-angiotensin system and blood pressure variability in rats].
Blanc J; Lambert G; Elghozi JL
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):1019-22. PubMed ID: 10989749
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
